Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sinco Pharmaceutical Holdings's annualizedNet Income for the quarter that ended in Dec. 2025 was HK$23 Mil.
Sinco Pharmaceutical Holdings's average Total Assets over the quarter that ended in Dec. 2025 was HK$2,048 Mil. Therefore, Sinco Pharmaceutical Holdings's annualized ROA % for the quarter that ended in Dec. 2025 was 1.13%.
The historical rank and industry rank for Sinco Pharmaceutical Holdings's ROA % or its related term are showing as below:
HKSE:06833'
s ROA % Range Over the Past 10 Years
Min: -38.27 Med: 2.77 Max: 11.62
Current: 1.84
During the past 12 years, Sinco Pharmaceutical Holdings's highest ROA % was 11.62%. The lowest was -38.27%. And the median was 2.77%.
HKSE:06833's ROA % is ranked worse than 60% of 120
companies
in the Medical Distribution industry
Industry Median: 2.38
vs HKSE:06833: 1.84
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Sinco Pharmaceutical Holdings ROA % Related Terms
Sinco Pharmaceutical Holdings ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinco Pharmaceutical Holdings ROA % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's ROA % distribution charts can be found below:
* The bar in red indicates where Sinco Pharmaceutical Holdings's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Sinco Pharmaceutical Holdings (HKSE:06833) has a ROA % of 1.13% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sinco Pharmaceutical Holdings and its competitors. This is 59% below median its historical median of 2.77. According to the industry distribution chart, Sinco Pharmaceutical Holdings ranks #72 out of 120 companies in the Medical Distribution industry, placing it in the top 60%.
Is Sinco Pharmaceutical Holdings' ROA % too high?
Sinco Pharmaceutical Holdings' current ROA % of 1.13% is 59% below median its 10-year median of 2.77. The Medical Distribution industry median ROA % is 2.38. Sinco Pharmaceutical Holdings' value of 1.13% is 52.5% below this industry median. Based on the distribution chart, Sinco Pharmaceutical Holdings ranks #72 out of 120 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' ROA % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinco Pharmaceutical Holdings ranks #72 out of 120 companies for ROA %. This places Sinco Pharmaceutical Holdings in the lower half of its industry. The industry median ROA % is 2.38. Sinco Pharmaceutical Holdings' value of 1.13% is 52.5% below this benchmark. While the company's 10-year median is 2.77 vs. the industry median of 2.38, Sinco Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.38, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinco Pharmaceutical Holdings's current ROA % of 1.13% is 52.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sinco Pharmaceutical Holdings and its competitors. For the Medical Distribution industry, the median ROA % is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinco Pharmaceutical Holdings's current ROA % is 1.13%, which is 59% below median its own 10-year median of 2.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.17 — trading 12.6% below its estimated fair value. The current ROA % is 1.13%, which is 59% below median its 10-year median of 2.77 and 52.5% below the Medical Distribution industry median of 2.38. Sinco Pharmaceutical Holdings' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current ROA % is 1.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of HK$0.17 is trading 12.6% below its estimated GF Value™ of HK$0.19.
GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:06833:
ROA %: 1.13% (59% below median its 10-year median of 2.77)
GF Value™: HK$0.19 vs. price of HK$0.17 (12.6% below fair value)
Industry Position: 52.5% below the Medical Distribution median (#72 of 120)
No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
44GF Score
Get the complete analysis for HKSE:06833
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06833 has been successfully added to your 
